DAMOUR, Alexia; FAURE, Muriel; LANDREIN, Nicolas; RAGUES, Jessica; ARDAH, Narda; DHAIDEL, Haneen; LAFON, Marie-Edith; WODRICH, Harald; BASHA, Walid

doi:10.3390/vaccines12050493

DAMOUR, Alexia
Microbiologie Fondamentale et Pathogénicité [MFP]

FAURE, Muriel
Microbiologie Fondamentale et Pathogénicité [MFP]

LANDREIN, Nicolas
Microbiologie Fondamentale et Pathogénicité [MFP]

Langue

Article de revue

Ce document a été publié dans

Vaccines. 2024-05-03, vol. 12, n° 5

Résumé en anglais

Since the beginning of the COVID-19 pandemic, different viral vector-based and mRNA vaccines directed against the SARS-CoV-2 "S" spike glycoprotein have been developed and have shown a good profile in terms of safety and efficacy. Nevertheless, an unbiased comparison of vaccination efficiency, including post-vaccination neutralizing activity, between the different vaccines remains largely unavailable. This study aimed to compare the efficacy of one mRNA (BNT162b2) and two non-replicating adenoviral vector vaccines (ChAdOx1 nCoV-19 and Sputnik V) in a cohort of 1120 vaccinated Palestinian individuals who received vaccines on an availability basis and which displayed a unique diversity of genetic characteristics. We assessed the level of anti-S antibodies and further determined the antibody neutralizing activity in 261 of those individuals vaccinated with BNT162b2a (121), ChAdOx1 (72) or Sputnik V (68). Our results showed no significant difference in the distribution of serum-neutralizing activity or S-antibody serum levels for the three groups of vaccines, proving equivalence in efficacy for the three vaccines under real-life conditions. In addition, none of the eight demographic parameters tested had an influence on vaccination efficacy. Regardless of the vaccine type, the vaccination campaign ultimately played a pivotal role in significantly reducing the morbidity and mortality associated with COVID-19 in Palestine.< Réduire

URI

https://oskar-bordeaux.fr/handle/20.500.12278/202034

DOI

http://dx.doi.org/10.3390/vaccines12050493

Unités de recherche

MFP (Laboratoire Microbiologie Fondamentale et Pathogénicité) - UMR 5234

Voir/Ouvrir

Métadonnées

Partager cette publication !

Licence d’utilisation du document

The Equal Neutralizing Effectiveness of BNT162b2, ChAdOx1 nCoV-19, and Sputnik V Vaccines in the Palestinian Population.

Langue

Ce document a été publié dans

Résumé en anglais

URI

DOI

Unités de recherche